Quick Answer: Topical GHK-Cu trial concentrations range from 0.1% to 2%, with most positive trials in the 0.1% to 1% range Apply a thin layer to clean, dry skin once or twice daily
This small size enables efficient penetration of biological barriers, including the skin
WHO updates list of drug-resistant bacteria most threatening to human health
The duration of exposure to tirzepatide in weight management trials was relatively short for cancer surveillance
Others consider significant reduction in symptoms a win, especially after years of chronic problems
Injection route (subcutaneous or intramuscular), exact dose, and frequency may vary and are determined by your provider based on your health history, goals, and response to time